Literature DB >> 3828557

On mathematical modeling of critical variables in cancer treatment (goals: better understanding of the past and better planning in the future).

H E Skipper.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3828557     DOI： 10.1007/bf02459681

Source DB:  PubMed          Journal:  Bull Math Biol        ISSN： 0092-8240            Impact factor:   1.758


× No keyword cloud information.
  11 in total

1.  EXPERIMENTAL EVALUATION OF POTENTIAL ANTICANCER AGENTS. XIII. ON THE CRITERIA AND KINETICS ASSOCIATED WITH "CURABILITY" OF EXPERIMENTAL LEUKEMIA.

Authors:  H E SKIPPER; F M SCHABEL; W S WILCOX
Journal:  Cancer Chemother Rep       Date:  1964-02

2.  Deveopment of resistance to combinations of six antimetabolites in mice with L1210 leukemia.

Authors:  F A Schmid; D J Hutchison; G M Otter; C C Stock
Journal:  Cancer Treat Rep       Date:  1976-01

Review 3.  Progress and perspectives in the chemotherapy of acute leukemia.

Authors:  E Frei; E J Freireich
Journal:  Adv Chemother       Date:  1965

Review 4.  The importance of dose intensity in chemotherapy of metastatic breast cancer.

Authors:  W Hryniuk; H Bush
Journal:  J Clin Oncol       Date:  1984-11       Impact factor: 44.544

Review 5.  The forty-year-old mutation theory of Luria and Delbrück and its pertinence to cancer chemotherapy.

Authors:  H E Skipper
Journal:  Adv Cancer Res       Date:  1983       Impact factor: 6.242

6.  Rationale for the use of alternating non-cross-resistant chemotherapy.

Authors:  J H Goldie; A J Coldman; G A Gudauskas
Journal:  Cancer Treat Rep       Date:  1982-03

7.  The last surviving cancer cell: the chances of killing it.

Authors:  W S Wilcox
Journal:  Cancer Chemother Rep       Date:  1966-11

8.  Tumor stem cell heterogeneity: implications with respect to classification of cancers by chemotherapeutic effect.

Authors:  H E Skipper; F M Schabel
Journal:  Cancer Treat Rep       Date:  1984-01

9.  Quantitative model for multiple levels of drug resistance in clinical tumors.

Authors:  J H Goldie; A J Coldman
Journal:  Cancer Treat Rep       Date:  1983-10

10.  A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate.

Authors:  J H Goldie; A J Coldman
Journal:  Cancer Treat Rep       Date:  1979 Nov-Dec
View more
  9 in total

1.  The population dynamics of antimicrobial chemotherapy.

Authors:  M Lipsitch; B R Levin
Journal:  Antimicrob Agents Chemother       Date:  1997-02       Impact factor: 5.191

2.  Dynamical properties of a minimally parameterized mathematical model for metronomic chemotherapy.

Authors:  Heinz Schättler; Urszula Ledzewicz; Behrooz Amini
Journal:  J Math Biol       Date:  2015-06-19       Impact factor: 2.259

Review 3.  Molecular biology of breast cancer metastasis. The use of mathematical models to determine relapse and to predict response to chemotherapy in breast cancer.

Authors:  S E Clare; F Nakhlis; J C Panetta
Journal:  Breast Cancer Res       Date:  2000-07-21       Impact factor: 6.466

4.  (31) P and (1) H MRS of DB-1 melanoma xenografts: lonidamine selectively decreases tumor intracellular pH and energy status and sensitizes tumors to melphalan.

Authors:  Kavindra Nath; David S Nelson; Andrew M Ho; Seung-Cheol Lee; Moses M Darpolor; Stephen Pickup; Rong Zhou; Daniel F Heitjan; Dennis B Leeper; Jerry D Glickson
Journal:  NMR Biomed       Date:  2012-06-29       Impact factor: 4.044

5.  Relapse or eradication of cancer is predicted by peptide-major histocompatibility complex affinity.

Authors:  Boris Engels; Victor H Engelhard; John Sidney; Alessandro Sette; David C Binder; Rebecca B Liu; David M Kranz; Stephen C Meredith; Donald A Rowley; Hans Schreiber
Journal:  Cancer Cell       Date:  2013-04-15       Impact factor: 31.743

6.  Angiogenesis and chemotherapy resistance: optimizing chemotherapy scheduling using mathematical modeling.

Authors:  Mariusz Bodzioch; Piotr Bajger; Urszula Foryś
Journal:  J Cancer Res Clin Oncol       Date:  2021-05-29       Impact factor: 4.553

7.  Early multidrug resistance, defined by changes in intracellular doxorubicin distribution, independent of P-glycoprotein.

Authors:  G J Schuurhuis; H J Broxterman; J H de Lange; H M Pinedo; T H van Heijningen; C M Kuiper; G L Scheffer; R J Scheper; C K van Kalken; J P Baak
Journal:  Br J Cancer       Date:  1991-11       Impact factor: 7.640

8.  Impact of Cisplatin Dosing Regimens on Mammary Tumor Growth in an Animal Model.

Authors:  James A Koziol; Theresa J Falls; Jan E Schnitzer
Journal:  Arch Cancer Biol Ther       Date:  2020-06-15

9.  On the Role of the Objective in the Optimization of Compartmental Models for Biomedical Therapies.

Authors:  Urszula Ledzewicz; Heinz Schättler
Journal:  J Optim Theory Appl       Date:  2020-09-30       Impact factor: 2.249
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.